Maurizio Valeriani
Overview
Explore the profile of Maurizio Valeriani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
527
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ingrosso G, Ponti E, Francolini G, Caini S, Fondelli S, Santini R, et al.
Radiol Med
. 2024 Feb;
129(4):643-652.
PMID: 38369638
Background: Moderate hypofractionated radiotherapy is a treatment option for the cure of localized prostate cancer (PCa) patients based on the results of randomized prospective trials, but there is a clinical...
2.
Valeriani R, Bruno E, Ribuffo D, Valeriani M
JPRAS Open
. 2024 Jan;
39:181-190.
PMID: 38283864
Background: The cephalic trim allows the remodeling of the alar cartilages by removing the cranial portion of the lower-lateral cartilages; this resection determines raising the tip of the nose through...
3.
Caivano D, Bonome P, Pezzulla D, Rotondi M, Sigillo R, De Sanctis V, et al.
Front Oncol
. 2023 Aug;
13:1163213.
PMID: 37601675
Introduction: Lymph node metastases (NMs) are a common site of tumor spread that can occur at different times of the disease. Stereotactic body radiation therapy (SBRT) can be a therapeutic...
4.
Facondo G, Serio M, Vullo G, Bianchi M, Pelliccia S, Di Rocco A, et al.
J Clin Med
. 2023 Jun;
12(11).
PMID: 37297971
Background: In order to evaluate the efficacy of residual site radiation therapy (RSRT) in terms of progression-free survival (PFS) and overall survival (OS) in patients with primary mediastinal lymphoma (PMBCL)...
5.
Rotondi M, Facondo G, Mossa S, Vullo G, Angelicone I, Valeriani M, et al.
Int J Colorectal Dis
. 2023 May;
38(1):125.
PMID: 37171509
Purpose: To compare toxicity of radiotherapy (RT) with concomitant chemotherapy (CHT) in patients (pts) with anal cancer treated with simultaneous integrated boost (SIB) versus sequential boost (SeqB). Methods: Sixty-six patients...
6.
De Sanctis V, Facondo G, Vullo G, Anzellini D, Sanguineti G, Nardangeli A, et al.
Cancer Diagn Progn
. 2023 Mar;
3(2):194-200.
PMID: 36875316
Background/aim: To evaluate the outcome and toxicities in patients with locally advanced cervical cancer (LACC) treated with radiochemotherapy and intracavitary brachytherapy. Patients And Methods: This study included 67 patients with...
7.
Facondo G, Vullo G, De Sanctis V, Rotondi M, Sigillo R, Valeriani M, et al.
J Pers Med
. 2023 Feb;
13(2).
PMID: 36836463
Background: To evaluate clinical outcomes of stereotactic body radiation therapy (SBRT) as a local treatment for lymph node metastases from gynecological cancers. Methods: Between November 2007 and October 2021, we...
8.
Valeriani R, Firmani G, Valeriani M
Plast Reconstr Surg Glob Open
. 2022 Oct;
10(10):e4556.
PMID: 36212084
Darwin's tubercle (DT) is a congenital outer ear deformity characterized by a posterior thickening of the auricular helix. It is particularly common in certain ethnic groups, with reports ranging between...
9.
Facondo G, Vullo G, De Sanctis V, Vitiello C, Nieddu L, Alfo M, et al.
J Contemp Brachytherapy
. 2022 Oct;
14(4):341-346.
PMID: 36199948
Purpose: To examine quality of life (QOL) and sexual functioning in a series of patients with intermediate- and high-intermediate risk endometrial cancer, treated with exclusive adjuvant one week high-dose-rate (HDR)...
10.
Valeriani M, Di Staso M, Facondo G, Vullo G, De Sanctis V, Gravina G, et al.
J Clin Med
. 2022 Aug;
11(16).
PMID: 36013023
Background: To evaluate outcomes in terms of survival and toxicity in a series of intermediate-risk prostate cancer (PCa) patients treated with hypofractionated radiotherapy (HyRT) + hormonal therapy (HT) with or...